Key terms

About RMD

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest RMD news

Today 12:20am ET Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Merck & Company (MRK) Mar 22 5:20am ET Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS) Mar 22 5:10am ET Analysts Are Bullish on These Healthcare Stocks: Addus Homecare (ADUS), Resmed (RMD) Mar 20 2:38pm ET LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint Mar 07 9:55am ET Early notable gainers among liquid option names on March 7th Mar 06 9:08am ET ResMed announces launch of AirFit F40 Feb 06 9:55am ET Tesla downgraded, UPS upgraded: Wall Street’s top analyst calls Feb 06 4:48am ET ResMed resumed with an Overweight at KeyBanc Jan 30 11:15pm ET Oppenheimer Keeps Their Buy Rating on Resmed (RMD) Jan 30 8:51pm ET Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Demant (OtherWILLF) Jan 30 6:38am ET ResMed price target raised to $215 from $195 at Mizuho Jan 29 7:36am ET Resmed Stock Buy Rating Affirmed Amidst Market Opportunity and Strong Financials Jan 26 7:00am ET ResMed price target raised to $195 from $180 at Mizuho Jan 25 6:48pm ET ResMed CEO: Our resupply rate is higher due to GLP-1 drugs Jan 25 9:55am ET Early notable gainers among liquid option names on January 25th Jan 25 9:47am ET ResMed rises 10.4% Jan 25 9:27am ET ResMed price target raised to $182 from $181 at RBC Capital Jan 25 8:10am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Jan 25 7:35am ET ResMed price target raised to $215 from $180 at Needham Jan 25 7:32am ET Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Resmed (RMD) and Clinigence Holdings (NUTX) Jan 25 6:25am ET Resmed Receives Strong Buy Rating on Robust Sales, Margin Expansion, and Promising Treatment Synergies Jan 25 6:25am ET ResMed price target raised to $198 from $195 at JPMorgan Jan 25 6:05am ET Buy Rating Affirmed for Resmed on Strong Financials and Positive Strategic Outlook Jan 25 4:28am ET ResMed Announces Quarterly Cash Dividend Payout Jan 24 4:10pm ET ResMed reports Q2 diluted EPS $1.88, consensus $1.79 Jan 24 3:34pm ET ResMed options imply 5.1% move in share price post-earnings Jan 23 6:40am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Jan 23 12:51am ET SPY ETF Update, 1/23/2024 Jan 19 12:28am ET SPY ETF Update, 1/19/2024 Jan 18 1:12pm ET FDA reports certain ResMed masks recalled due to safety issue with magnets Jan 10 3:20am ET Analysts’ Top Healthcare Picks: Evolent Health (EVH), Vertex Pharmaceuticals (VRTX)

No recent news articles are available for RMD

No recent press releases are available for RMD

RMD Financials

1-year income & revenue

Key terms

RMD Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

RMD Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms